Seasonal influenza viruses (IAV) are a common cause of acute respiratory illness worldwide and generate a significant socio-economic burden. IAV rapidly mutate, necessitating annual vaccine reformulation as traditional vaccines do not typically induce broad-spectrum immunity. In addition to seasonal infections, emerging pandemic influenza viruses present a continued threat to global public health. Pandemic influenza viruses have consistently higher attack rates and are typically associated with greater mortality as compared to seasonal strains. Ongoing strategies to improve vaccine efficacy typically focus on providing broad-spectrum immunity, and while both B and T cells can mediate heterosubtypic responses, typical vaccine development will augment either humoral or cellular immunity. However, multipronged approaches, targeting several antigens, may limit the generation of viral escape mutants. There are few vaccine platforms that can deliver multiple antigens and generate robust cellular and humoral immunity. In this work, we describe a novel vaccination strategy, tested pre-clinically in mice, for the delivery of novel bivalent viral-vectored vaccines. Here, we show this strategy elicits potent T cell responses toward highly conserved internal antigens, whilst simultaneously inducing high levels of antibodies towards hemagglutinin (HA). Importantly, these humoral responses generate longlived plasma cells and generate antibodies capable of neutralising variant HA-expressing pseudotyped lentiviruses. Significantly, these novel viral-vectored vaccines induce strong immune responses capable of conferring protection in a stringent influenza A virus challenge.
Introduction
Seasonal influenza A virus (IAV) infections cause significant morbidity and mortality worldwide and remain a major public health concern. The novel avian-origin influenza A strain (H7N9), initially identified in 2013, is now circulating with almost annual frequency and accounted for one-third of all cases n the 2016/2017 influenza season. Most worringly, the case-fatality rate for this virus exceeds 40% (1) (2) (3) . In addition, H7N9 influenza viruses have recently been assessed as having the highest potential pandemic risk of any novel influenza A viruses; this assessment is based on recent studies which indicate that H7N9 viruses have increased genetic diversity, geographical distribution, and in recent outbreaks a significantly higher proportion of H7N9-infected patients have needed care in an ICU (1) (2) (3) . For the past 70 years vaccination has been the mainstay healthcare strategy against influenza infection (4) (5) (6) . However traditional inactivated influenza vaccines (IIVs) confer strain-specific protection and do not typically induce the broad-spectrum immunity needed in the face of a newly emergent IAV (7) (8) (9) . The possible threat of a pandemic outbreak has therefore catalysed the development of broadly protective IAV vaccines.
Recent strategies to augment and broaden vaccine efficacy have shifted towards the development of 'universal' vaccines capable of providing heterosubtypic protection against multiple, or possibly all subtypes of IAV. While both humoral and cellular immunity can mediate heterosubtypic responses, inducing antibodies against the more conserved stalk domain of hemagglutinin (HA) has been the recent focus of many vaccine programmes (10, 11) . However, multipronged approaches, targeting several antigens inducing both humoral and cellular responses may limit the generation of viral escape mutants compared to vaccines targeting a limited number of protective epitopes on the HA stalk . There are few vaccine technologies that will facilitate the delivery of multiple antigens to generate robust cellular and humoral immunity toward infectious disease antigens. Viral-vectored vaccines have been developed for the induction of strong humoral and potent cellular immunity toward encoded antigens. An added strength of this platform is that viral vectors can accommodate more than one antigen (12) . For heterologous prime-boost vaccination strategies, typically, one viral vector (e.g. Chimpanzee Adenovirus (ChAd)) encoding the target antigen(s) is used for the priming vaccination and a different platform, most often Modified Vaccinia Ankara (MVA), is used for the boost or repeat vaccination. In the present study we describe novel ChAd and MVA-vectored vaccines designed to simultaneously induce heterosubtypic and protective B and T cell responses against three influenza A antigens, HA, NP and M1. Using a heterologous prime-boost strategy, we induce high levels of heterosubtypic and homologous immune responses targeting the major virion surface protein, HA and the conserved internal viral antigens NP and M1. We demonstrate protection, post prime-boost, vaccination in a stringent challenge model of mouse adapted avian IAV.
Materials and Methods

Recombinant ChAd and MVA vaccines
The construction of ChAdOx1 NP+M1 has been described previously (13) . Details of the viral vectored vaccines used in these studies are as described in Table I (TYQRTRALV) were added typically at 2 g/mL.
ELISA ELISA was performed essentially as described (14) . Nunc Maxisorp® 96-well plates were coated with 0.1 g recombinant protein (H7HA protein was produced in-house as described (16) (14, 17) .
IgG Antibody Secreting Cell ELISPOT Assay
Bone marrow IgG Antibody Secreting Cell ELISPOT Assay was performed as described (18, 19) using approximately 1x10 7 cells/mL in complete Iscove's that had been rested overnight.
MultiScreen-IP filter plates were coated with 0.5 g recombinant HA while negative control wells were coated with irrelevant protein (0.5 g ovalbumin).
Pseudotype Neutralisation Assay
Starting with an initial 1:40 dilution, test sera was diluted 2-fold in complete DMEM and assayed as described (14) Results were normalized relative to cell-only and pseudotyped lentivirus-only wells and expressed as the percentage of inhibition of pseudotyped lentivirus entry (neutralisation). The half maximal inhibitory concentration (IC 50 ) was calculated using GraphPad Prism 6 software. mice that lost 25% or more of their initial body weight were euthanized.
Challenge
Statistics
Statistical analyses were carried out using GraphPad Prism software version 6 (GraphPad Software, La Jolla, CA). Data was tested for normal distribution and the appropriate statistical analysis applied. While no significant differences, post viral vector vaccination, were detected between the median H7HA-specific IgG antibodies, at two weeks ( Figure 3B ), all responses induced by vaccination with ChAdOx1-vectored vaccines encoding H7HA were significantly higher compared to vaccination with 10 g recombinant H7HA (**p≤0.01) (Figure 3 B ). These data demonstrate that vaccination with ChAdOx1-vectored vaccines expressing H7HA elicits superior humoral immunity compared to protein, and moreover these responses are maintained in multi-antigen vaccination regimens.
Results
Immunogenicity of Novel
Prime-Boost Regimen Incorporating Simian Adenoviral Vectors and Poxviral Vectors
Expressing NP+M1 and H7HA
Adenovirus-MVA prime-boost regimens are currently one of the leading strategies to induce potent immune responses against vaccine antigens (21, 22) . BALB/c mice (n=18 (6 per group)) received a priming vaccination of either ChAdOx1-NP+M1, ChAdOx1-H7, or both, administered separately into opposite limbs, as described. At eight weeks post-prime all groups were boosted with MVA-NP+M1-H7
T Cell Responses Following Prime-Boost vaccination
Splenic cells were isolated 2 weeks post prime and post-boost in order to assess T cell responses against NP+M1 and H7HA. Consistent with previous data, NP [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] specific T cell responses were slightly higher in mice primed with ChAdOx1 NP+M1 when compared to ChAdOx1
NP+M1 and ChAdOx1-H7 administered into opposite limbs ( Figure 4A ). However, following the MVA vaccination, T cell responses against NP+M1 were boosted approximately five-fold higher in all groups and there were no significant differences, after boost toward NP+M1 antigen between mice that were primed with either ChAdOx1 NP+M1 or co-administration of ChAdOx1 As expected, mice primed only with ChAdOx1 NP+M1 had no detectable H7HA-specific T cell responses ( Figure 4B&C , column 1). There were no significant differences between the H7HA-specific T cell responses, two weeks post prime or post boost between mice vaccinated with ChAdOx1-H7 or ChAdOx1-H7 co-administered with ChAdOx1 NP+M1 (Figure 4) . Collectively these results demonstrate that vaccination with either ChAdOx1-H7 or co-administration of ChAdOx1 NP+M1 and ChAdOx1-H7 followed by immunisation with MVA-NP+M1-H7
induces heterosubtypic T cell responses against H7HA.
Humoral responses
Serum was collected at 2 and 8 weeks post prime and also post boost vaccinations and the longevity of antibody responses were followed out to 26 weeks following the initial immunzation. Mice primed with ChAdOx1-H7 or ChAdOx1-H7 and ChAdOx-NP+M1 had higher total IgG against H7HA at all time points compared to vaccination with either protein alone or with ChAdOx1 NP+M1 followed by MVA-NP+M1-H7 ( Figure 5A ). 
Functionality of Adaptive Immune Responses Following ChAdOx1 -MVA Prime-Boost Vaccination Pseudotype Virus Neutralisation
In order to assess the breadth of anti-HA antibody functionality, sera collected 8 weeks after boosting with MVA-NP+M1-H7 was assayed against a number of pseudotyped lentiviruses.
Two strains of H7HA pseudotypes were tested, A/chicken/Italy/1082/1999 (H7N1), a low pathogenic avian influenza (LPAI) strain closely (98% at the amino acid level) related to the vaccine immunogen, and A/Shanghai/2/2013 (H7N9) (96% at the amino acid level), the novel H7N9 first identified in humans in 2013. A third group 2 HA lentivirus, expressing a different subtype, H3HA from A/Udorn/307/1972 (H3N2) (48% at the amino acid level), was also tested.
Pooled sera from mice primed with ChAdOx1-H7 or ChAdOx1-H7 and ChAdOx1 NP+M1 completely neutralized both H7 pseudotypes at all serum dilutions tested (Table II) . In addition,
IC 50 values from mice primed with ChAdOx1 NP+M1 and boosted with MVA-NP+M1-H7 were higher compared to mice vaccinated with protein alone. IC 50 values against the H3N2 pseudotype lentivirus were comparable between all groups vaccinated with viral vectors but lower in the control group vaccinated with protein alone (Table II) .
Prime-boost vaccinated mice intranasally challenged with divergent pandemic H7N9 IAV
To assess heterosubtypic protective efficacy, mice were vaccinated, as described, and challenged (1). However most recently more than 600 new cases have been reported during the fifth wave of H7N9 (start of 2017), which is now the biggest wave since human infection wsa first detected with a worringly, high the case-fatality rate (40% (1-3) ). Consequently, there is an ongoing and pressing need for vaccines that can protect against avian derived influenza viruses, especially
given that H7N9 viruses now exhibit a seasonal pattern of circulation World Health Organization 2015).
Clinical development of influenza vaccines is ongoing, however split virus or subunit vaccines for avian influenza are known to be poorly immunogenic (26, 27) and often require multiple doses and/or formulation with potent adjuvants to achieve seroconversion (28) . Although live attenuated vaccines (LAIVs) can induce of both humoral and cellular immunogenicity, in adults these vaccines have previously been associated with lower seroconversion rates and higher rates of laboratory-confirmed influenza when compared to trivalent influenza vaccine. These phenomena may possibly due to pre-existing immunogenicity at mucosal sites (7, 29, 30) . Less than half of the vaccinees in a recent phase I clinical trial assessing safety and immunogenicity of a H7N9 LAIVs seroconverted (48%, (95% CI 29 4-67 5)) after one vaccination (31) .
Vaccines that target conserved antigens, such as internal proteins of influenza A viruses, may provide greater cross-protective responses toward diverse influenza strains including newly emergent pandemic variants. We demonstrate that while mice primed with ChAdOx1 NP+M1
and boosted with MVA-NP+M1-H7 had significantly less HA-specific antibodies ( Figure 5) there was no difference in morbidity or mortality, compared to a protein and adjuvant only regimen ( Figure 6 ). These data, highlight and confirm that T cells confer a degree of protection against the clinical symptoms of influenza A virus infection. Most commercially available influenza vaccines primarily induce strain-specific antibodies, however it has been demonstrated that heterosubtypic T cells can confer broad-spectrum protection (32) (33) (34) . A correlation between IAV-directed T cells and reduced viral shedding with less severe illness in humans has been demonstrated in a number of clinical studies (32, 33, 35) . It has also been demonstrated that protective levels of NP-specific T cell responses are found in 43% of the adult population (36) .
Importantly, if a vaccine can boost the numbers of pre-existing influenza-specific T cells into this protective range, these vaccinees would be conferred a degree of protection toward newly pandemic influenza viruses. This level of boosting is achievable with clinical vaccination with MVA-NP+M1 in humans (37) . In the event of a virulent pandemic outbreak, vaccination with MVA-NP+M1 could curb disease symptoms while the strain specific HA protein or vaccine modality encoding the outbreak HA antigen could be manufactured. Follow-on vaccination with a strain specific HA could then provide neutralising antibodies toward emergent viruses and curb disease transmission.
Advantageously, viral-vectored vaccines can facilitate delivery of multiple disease-specific antigens, which is thought to be key in curbing viral escape mutants when compared to vaccines that target a single antigen. However, delivery of multiple antigens can result in immune competition (38, 39) , which can be largely circumvented by administration of the viral-vectored vaccine encoded antigens to separate sites as described here. While the exact mechanisms of antigenic interference following vaccination remains unknown, this phenomenon is thought to be influenced by spatial constraints on T cells (40, 41) . Balb/c mice were unvaccinated or received an irrelevant ChAdOx1 prime and MVA boost vaccination. All other groups were vaccinated as described and three weeks after the last
